PUK15 MODELLING COST-EFFECTIVENESS USING A DYNAMIC PRICE PATH WITH GENERIC SUBSTITUTION SCENARIOS: COSTEFFECTIVENESS OF CINACALCET IN UK PATIENTS WITH END-STAGE RENAL DISEASE (ESRD) ON HEMODIALYSIS
نویسندگان
چکیده
منابع مشابه
Dentomaxillofacial Radiographic Changes in a Group of Iranian Patients with End Stage Renal Disease Undergoing Hemodialysis
Introduction: This study aims to evaluate the dentomaxillofacial radiographic changes in end stage renal disease (ESRD) patients who were on hemodialysis. Methods: Parathyroid hormone (PTH), calcium, phosphorus and alkaline phosphatase (ALP) measurements, as well as Panoramic and periapical radiographs were obtained from seventy four patients with a history of end stage renal disease (ESRD). Re...
متن کاملETIOLOGY OF END STAGE RENAL DISEASE (ESRD) IN SHIRAZ PEDIATRIC HEMODIALYSIS CENTER
One-hundred and sixteen children with ESRD were registered in Shiraz Pediatric Hemodialysis Center in Nemazee Hospital, a referral center in the south of Iran, from 1990 to 1999. Very small children are not dialysed in this center due to technical problems. The age range of children in this center was 2-16 years, mean age was 10.4±3.6 years and male to female ratio was 1.4. Major causes of ...
متن کاملHemoglobin And Hematocrit Rise In End-Stage Renal Disease (ESRD) With PDpoetin: Results Of A Phase Ш, Multicenter Clinical Trial
Background and Objective: The anemia of ESRD is a complex disorder, associated with serious complications, which increases patients’ mortality and morbidity. Treatment of this anemia with recombinant human erythropoietin (rh-EPO) is well established. This clinical trial study was conducted within 20 months, from May 2005 to December 2006, in order to evaluate the efficacy of PDpoetin (rh-EPO...
متن کاملModelling the Cost-Effectiveness of Delaying End-Stage Renal Disease
Background: As the incidence of end-stage renal disease (ESRD) is on the rise, new therapies are being developed for delaying ESRD. This study is aimed at constructing a generic model for estimating the cost-effectiveness of delaying ESRD in 7 European countries: the Netherlands, United Kingdom, Germany, Italy, Spain, Finland and Hungary. The use of this model is illustrated by assessing 2 fict...
متن کاملModelling the Cost-Effectiveness of Delaying End-Stage Renal Disease.
BACKGROUND As the incidence of end-stage renal disease (ESRD) is on the rise, new therapies are being developed for delaying ESRD. This study is aimed at constructing a generic model for estimating the cost-effectiveness of delaying ESRD in 7 European countries: the Netherlands, United Kingdom, Germany, Italy, Spain, Finland and Hungary. The use of this model is illustrated by assessing 2 ficti...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2006
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(10)63782-5